slightly when captopril was given after dialysis (which we also observed in three of our patients). A third captopril test performed after he had lost a further 1 2 kg led to profound orthostatic hypotension. Although this may have been caused by captopril, nearly two hours elapsed between control pressure measurements and administration of captopril. Failure of physiological buffer mechanisms to maintain blood pressure during this period of intravascular volume depletion, rather than the action of captopril, may have been responsible for the augmented postural decline in blood pressure. In contrast, each patient in our study had a stable blood pressure in an upright, seated position for at least 30 minutes before receiving captopril.
The same authors have recently extended their studies.1 7 They observed reductions in blood pressure in seven anephric patients when captopril was given one hour after haemodialysis. Administering captopril 24 hours after dialysis, however, did not produce a hypotensive effect, which is consistent with our present findings. Thus the fall in blood pressure occurred only when captopril was given soon after dialysis, which suggests a mechanism related to the haemodialysis procedure Case report A man aged 59 years was admitted with all the signs and symptoms of a nephrotic syndrome. At work he had been exposed for prolonged periods to hydrocarbon derivatives. The figure shows the changes in proteinuria, albuminaemia, oedema, and body weight in relation to successive periods of contact with hydrocarbons and rest periods over 27 months of follow-up. The creatinine clearance remained normal, and the patient received no treatment. Clinical and laboratory investigations showed a close correlation between a worsening of the nephropathy and exposure to toxic products at work and the complete reversal of disease activity after leaving that job. Renal biopsy, carried out with light, immunofluorescence, and electron microscopy, showed the features of a membranous glomerulonephritis. Electron microscopy indicated that adjacent to small, probably recent, deposits on the subepithelial layer of the glomerular basement membrane were many deposits embedded in the membrane, and it also showed electronlucent lacunae. 
Comment
The finding of deposits embedded in the basement membrane and electron-lucent lacunae may be characteristic of many cases of idiopathic membranous glomerulonephritis. Successive exposures to hydrocarbons, however, are thought to be followed by a corresponding sudden rise in deposits or in situ formation of immunocomplexes at glomerular level. The immunocomplexes may consist of renal tubular epithelial components or plasma proteins that become antigenic on contact with the hydrocarbon, and the antibodies would be directed against these antigens.
Each period of contact with the hydrocarbons was quickly followed in our patient by an increase in proteinuria, which quickly disappeared when he was no longer exposed. We cannot therefore exclude the hypothesis of Lagrue et all that the inhaled toxin may alter the pulmonary alveolar macrophages. These changes would lead to the later release of enzymes or proinflammatory substances which, after a time, act on capillary permeability. Although the mechanism of glomerular injury induced by hydrocarbons may be unknown, our case gives further evidence of a cause-and-effect relation between hydrocarbon exposure and glomerulonephritis. Lagrue Neutropenia is not a common complication of antituberculous chemotherapy.' 2 We describe a patient who developed this unusual side effect on each of the three drugs used to treat his pulmonary tuberculosis.
Case report
A 75-year-old man presented with a two-month history of cough and purulent sputum. Examination showed hepatosplenomegaly and generalised lymphadenopathy. Discharging sinuses were associated with enlarged axillary lymph nodes, and there was also a sinus in the left parastemal region.
A chest radiograph showed miliary mottling. Haemoglobin was 10-3 g/dl, white cell count 4-2 x 109/1 4200/mm3 with 78 % neutrophils, and erythrocyte sedimentation rate 62 mm in the first hour. A Mantoux test was negative at 1/100, and no acid-alcohol fast bacilli were seen on direct examination of sputum. Bone-marrow examination showed nothing abnormal. Excision biopsy of an axillary lymph node showed caseating granulomata, and antituberculous chemotherapy was started with rifampicin 450 mg, isoniazid 300 mg, and ethambutol 25 mg/kg/day. In view of the patient's poor general condition prednisolone, 30 mg/day, was also prescribed. Culture of sinus fluid subsequently revealed Mycobacterium tuberculosis sensitive to the standard antituberculosis drugs. Both sputum and bone-marrow cultures proved negative.
His clinical and radiological response was good. Steroids were withdrawn after one month of chemotherapy but the white cell count then fell sharply. Antituberculosis drugs were discontinued for five days and then restarted together with prednisolone 30 mg/day. The white cell count recovered but more gradual withdrawal of prednisolone again resulted in leucopenia when the dose was reduced to less than 20 mg/day (see figure) .
Variations in total white cell count were produced by changes in the neutrophil count. Maintenance chemotherapy was attempted with combinations of rifampicin and isoniazid and isoniazid and ethambutol. On both combinations neutropenia complicated the attempt to discontinue prednisolone. All drugs were subsequently stopped, the white cell count returned to 4-4 x 109/1 (3 x Relation of white cell count and neutrophil count to drug regimen.
was rapid on both isoniazid and ethambutol, and the neutrophil count also fell in response to rifampicin. Although the initial drop was not so pronounced, the count continued to fall for a further week after rifampicin was discontinued. Treatment has since continued with rifampicin and isoniazid plus prednisolone 5 mg/day, and the patient has remained well with a normal white cell count.
Comment
Although rare, leucopenia is a recognised complication of isoniazid. It was first reported by Ferguson in 1952,3 and further case reports have followed. The exact incidence of this side effect is unknown.
There is no well-documented evidence of ethambutol-induced neutropenia. In a study of 196 patients with pulmonary tuberculosis randomly allocated to three treatment regimens Newman et al found leucopenia ( < 4 5 x 109/1) in 4-2% of 71 patients treated with rifampicin and isoniazid; in 10-8% of 65 patients treated with rifampicin, isoniazid, and ethambutol; and in 855% of 59 patients treated with streptomycin, isoniazid, and ethambutol.1 From these figures, the authors suggested an association of leucopenia with ethambutol, but challenge with individual drugs was not performed. Moreover, a current review of modem antituberculosis drug regimens2 reports a much lower incidence of leucopenia than described by Newman et al.
Mattson has reported the incidence of drug complications in 547 patients receiving intermittent rifampicin combined with daily isoniazid and ethambutol.4 A white cell count of less than 3 x 109/1 was observed in 20 patients, and half of these had systemic reactions of the sort associated with intermittent rifampicin therapy.
Leucopenia is sometimes seen in disseminated tuberculosis before chemotherapy is started. 5 This did not apply in our patient. Massive killing of mycobacteria might result in the release of substances which could depress white cell production, but such a phenomenon is unlikely to have occurred in our patient as leucopenia persisted into the stage when presumably only small numbers of bacilli were being killed. We can only postulate that this patient showed an idiosyncratic
